![Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)](https://publinestorage.blob.core.windows.net/b19a48f4-4061-46e6-b55c-8231ba2180a0/jcth-9-939-ga.jpg)
Pharmacological Therapeutics: Current Trends for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
![What's in a name? Renaming 'NAFLD' to 'MAFLD' - Fouad - 2020 - Liver International - Wiley Online Library What's in a name? Renaming 'NAFLD' to 'MAFLD' - Fouad - 2020 - Liver International - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/cb84ed96-620a-4937-bbd3-007dbff23aef/liv14478-fig-0001-m.jpg)
What's in a name? Renaming 'NAFLD' to 'MAFLD' - Fouad - 2020 - Liver International - Wiley Online Library
![Noninvasive biomarkers in NAFLD and NASH — current progress and future promise | Nature Reviews Gastroenterology & Hepatology Noninvasive biomarkers in NAFLD and NASH — current progress and future promise | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41575-018-0014-9/MediaObjects/41575_2018_14_Fig1_HTML.jpg)
Noninvasive biomarkers in NAFLD and NASH — current progress and future promise | Nature Reviews Gastroenterology & Hepatology
![Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis - Gastroenterology Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis - Gastroenterology](https://www.gastrojournal.org/cms/asset/43f8cafc-c3d3-4389-a591-0ed1cbe39fea/fx1.jpg)
Bariatric Surgery Provides Long-term Resolution of Nonalcoholic Steatohepatitis and Regression of Fibrosis - Gastroenterology
![American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings - Endocrine Practice American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings - Endocrine Practice](https://www.endocrinepractice.org/cms/attachment/3a8cc399-770d-4b1c-bb4f-90c14911a710/gr1.jpg)
American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings - Endocrine Practice
![PDF) The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study PDF) The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study](https://i1.rgstatic.net/publication/333800621_The_burden_of_non-alcoholic_steatohepatitis_NASH_among_patients_from_Europe_A_real-world_patient-reported_outcomes_study/links/5e42d55c299bf1cdb91fa8d0/largepreview.png)
PDF) The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study
![Cureus | Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review | Article Cureus | Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review | Article](https://assets.cureus.com/uploads/figure/file/317087/lightbox_6b69032079d211ec9cbe99b9b3f34ebd-Progression-Figure-1.png)
Cureus | Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review | Article
![New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis | SpringerLink New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs43440-019-00020-1/MediaObjects/43440_2019_20_Fig1_HTML.png)
New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis | SpringerLink
![From NASH to HCC: current concepts and future challenges | Nature Reviews Gastroenterology & Hepatology From NASH to HCC: current concepts and future challenges | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41575-019-0145-7/MediaObjects/41575_2019_145_Fig1_HTML.png)
From NASH to HCC: current concepts and future challenges | Nature Reviews Gastroenterology & Hepatology
![In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications - ScienceDirect In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2589004221015194-fx1.jpg)
In vitro models for non-alcoholic fatty liver disease: Emerging platforms and their applications - ScienceDirect
![Hormone identified that limits liver fibrosis - Potential applications for treating nonalcoholic steatohepatitis, cirrhosis - | Research at Kobe Hormone identified that limits liver fibrosis - Potential applications for treating nonalcoholic steatohepatitis, cirrhosis - | Research at Kobe](https://www.kobe-u.ac.jp/images/research_at_kobe_en/news/2016_10_13_01-1.jpg)